Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Ignite Creation Date:
2025-12-25 @ 2:18 AM
Ignite Modification Date:
2025-12-26 @ 12:48 AM
NCT ID:
NCT02935634
Description:
The total number at risk for all-cause mortality represents all participants who were randomized and re-randomized. The total number at risk by any serious adverse event and other (not including serious) adverse events represents all participants who received at least 1 dose of study medication.
Frequency Threshold:
5
Time Frame:
Participants were assessed for all-cause mortality from their randomization until their study completion (up to approximately 65 months). SAEs and other AEs were assessed from first dose to 100 days after last dose of study therapy (up to approximately 30 months).
Study:
NCT02935634
Study Brief:
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
Event Groups(If Any):
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Track 1: Nivolumab + Ipilimumab | Treatment naive participants received nivolumab 1 mg/kg via IV infusion followed by ipilimumab 3 mg/kg administered IV Q3W, followed 6 weeks after the last dose of combination study treatment by nivolumab 480 mg administered IV Q4W for 2 years. | 19 | None | 19 | 23 | 21 | 23 | View |
| Track 1: Nivolumab + BMS-986016 | Treatment naive participants received nivolumab 240 mg via IV infusion Q2W followed by BMS-986016 80 mg administered IV Q2W for 2 years. | 15 | None | 15 | 20 | 20 | 20 | View |
| Track 1: Nivolumab + BMS-986205 | Treatment naive participants received nivolumab 480 mg Q4W and BMS-986205 100 mg QD for 104 weeks. | 26 | None | 24 | 38 | 38 | 38 | View |
| Track 1: Nivolumab + Rucaparib | Treatment naive participants received nivolumab 480 mg administered IV Q4W in combination with rucaparib 600 mg administered orally twice daily for 2 years. | 7 | None | 5 | 7 | 7 | 7 | View |
| Track 1: Ipilimumab + Rucaparib | Treatment naive participants received ipilimumab 3 mg/kg administered IV Q4W in combination with rucaparib 600 mg orally twice daily for 2 years. | 5 | None | 6 | 8 | 8 | 8 | View |
| Track 1: Nivolumab + Ipilimumab + Rucaparib | Treatment naive participants received nivolumab 480 mg administered IV Q4W in combination with ipilimumab 1 mg/kg administered IV Q6W and rucaparib 600 mg orally twice daily for 2 years. | 4 | None | 4 | 6 | 6 | 6 | View |
| Track 2: Nivolumab + Ipilimumab | Treatment experienced participants received nivolumab 1 mg/kg via IV infusion followed by ipilimumab 3 mg/kg administered IV Q3W, followed 6 weeks after the last dose of combination study treatment by nivolumab 480 mg administered IV Q4W for 2 years. | 19 | None | 17 | 23 | 23 | 23 | View |
| Track 2: Nivolumab + BMS-986016 | Treatment experienced participants received nivolumab 240 mg via IV infusion Q2W followed by BMS-986016 80 mg administered IV Q2W for 2 years. | 26 | None | 24 | 36 | 34 | 36 | View |
| Track 2: Nivolumab + BMS-986205 | Treatment experienced participants received nivolumab 480 mg Q4W and BMS-986205 100 mg QD for 104 weeks. | 13 | None | 12 | 22 | 21 | 22 | View |
| Track 2: Nivolumab + Rucaparib | Treatment experienced participants received nivolumab 480 mg administered IV Q4W in combination with rucaparib 600 mg administered orally twice daily for 2 years. | 3 | None | 4 | 6 | 6 | 6 | View |
| Track 2: Ipilimumab + Rucaparib | Treatment experienced participants received ipilimumab 3 mg/kg administered IV Q4W in combination with rucaparib 600 mg orally twice daily for 2 years. | 2 | None | 2 | 2 | 2 | 2 | View |
| Track 2: Nivolumab + Ipilimumab + Rucaparib | Treatment experienced participants received nivolumab 480 mg administered IV Q4W in combination with ipilimumab 1 mg/kg administered IV Q6W and rucaparib 600 mg orally twice daily for 2 years. | 3 | None | 3 | 4 | 4 | 4 | View |
Serious Events(If Any):
Serious Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Febrile neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Supraventricular tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Adrenal insufficiency | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
| Upper gastrointestinal haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Upper respiratory tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Blood creatinine increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Tumour pain | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Pneumothorax | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Secondary adrenocortical insufficiency | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Abdominal pain upper | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Ascites | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Colitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Duodenal obstruction | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Gastric haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Gastric perforation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Haematemesis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Ileus | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Large intestinal obstruction | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Large intestine perforation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Oesophageal perforation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Oesophageal stenosis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Small intestinal obstruction | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Asthenia | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Chest discomfort | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Death | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| General physical health deterioration | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Multiple organ dysfunction syndrome | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Non-cardiac chest pain | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Performance status decreased | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Sudden death | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Systemic inflammatory response syndrome | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Autoimmune hepatitis | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Cholecystitis | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Hepatic failure | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Hepatic haematoma | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Hepatitis | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Hyperbilirubinaemia | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Portal vein thrombosis | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Atypical pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Clostridium difficile infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Ophthalmic herpes zoster | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Pneumocystis jirovecii pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Pneumonia viral | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Skin bacterial infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Streptococcal bacteraemia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Vascular device infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Wound infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Acetabulum fracture | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Femur fracture | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Procedural pain | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood bilirubin increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Hepatic enzyme increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Weight decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Failure to thrive | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hyperkalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hyponatraemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Metabolic acidosis | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Flank pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Intervertebral disc protrusion | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Muscular weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Cancer pain | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Keratoacanthoma | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Malignant neoplasm progression | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Metastases to central nervous system | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Tumour haemorrhage | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Tumour perforation | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Brain oedema | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Cerebral infarction | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Cerebrovascular accident | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Encephalopathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Haemorrhage intracranial | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Seizure | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Syncope | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Transient ischaemic attack | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Device dislocation | SYSTEMATIC_ASSESSMENT | Product Issues | 25.0 | View |
| Delirium | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Acute kidney injury | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 25.0 | View |
| Urinary tract obstruction | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 25.0 | View |
| Acute respiratory failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Aspiration | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Haemoptysis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Hypoxia | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Pulmonary embolism | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Respiratory failure | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Decubitus ulcer | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Embolism | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Superior vena cava stenosis | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Basedow's disease | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
| Lymphocytic hypophysitis | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
Other Events(If Any):
Other Events
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Leukocytosis | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Lymphadenopathy | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Lymphopenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Neutropenia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Atrial fibrillation | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Palpitations | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Sinus tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Dysphagia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Flatulence | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Influenza like illness | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Malaise | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Mucosal inflammation | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Non-cardiac chest pain | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Anaemia | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Coagulopathy | SYSTEMATIC_ASSESSMENT | Blood and lymphatic system disorders | 25.0 | View |
| Tachycardia | SYSTEMATIC_ASSESSMENT | Cardiac disorders | 25.0 | View |
| Cerumen impaction | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 25.0 | View |
| Vertigo | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | 25.0 | View |
| Hyperthyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
| Hypothyroidism | SYSTEMATIC_ASSESSMENT | Endocrine disorders | 25.0 | View |
| Vision blurred | SYSTEMATIC_ASSESSMENT | Eye disorders | 25.0 | View |
| Abdominal distension | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Abdominal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Abdominal pain lower | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Abdominal pain upper | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Ascites | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Colitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Constipation | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Diarrhoea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Dry mouth | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Dyspepsia | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Gastrooesophageal reflux disease | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Ileus | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Jejunal stenosis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Large intestinal obstruction | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Nausea | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Oesophageal pain | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Oesophageal stenosis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Rectal haemorrhage | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Stomatitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Vomiting | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | 25.0 | View |
| Asthenia | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Chills | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Early satiety | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Fatigue | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| General physical health deterioration | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Oedema peripheral | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Pain | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Pyrexia | SYSTEMATIC_ASSESSMENT | General disorders | 25.0 | View |
| Autoimmune hepatitis | SYSTEMATIC_ASSESSMENT | Hepatobiliary disorders | 25.0 | View |
| Bronchitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| COVID-19 | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Cellulitis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Clostridium difficile infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Genital herpes | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Lymph gland infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Paronychia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Pneumonia | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Sepsis | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Urinary tract infection | SYSTEMATIC_ASSESSMENT | Infections and infestations | 25.0 | View |
| Arthropod bite | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Contusion | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Fall | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Infusion related reaction | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | 25.0 | View |
| Activated partial thromboplastin time prolonged | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Alanine aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Amylase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Aspartate aminotransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood alkaline phosphatase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood bilirubin increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood creatine increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood creatine phosphokinase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood creatinine increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood pressure increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Blood urea increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| C-reactive protein increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Electrocardiogram QT prolonged | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Gamma-glutamyltransferase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Glomerular filtration rate decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| International normalised ratio increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Lipase increased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Lymph node palpable | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Lymphocyte count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Neutrophil count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Platelet count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Weight decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| White blood cell count decreased | SYSTEMATIC_ASSESSMENT | Investigations | 25.0 | View |
| Decreased appetite | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Dehydration | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hyperglycaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hyperkalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypermagnesaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypoalbuminaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypocalcaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypokalaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypomagnesaemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hyponatraemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Hypophosphataemia | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Iron deficiency | SYSTEMATIC_ASSESSMENT | Metabolism and nutrition disorders | 25.0 | View |
| Arthralgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Arthritis | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Chondrocalcinosis pyrophosphate | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Muscle spasms | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Muscular weakness | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Musculoskeletal chest pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Musculoskeletal pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Neck pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Pain in extremity | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Sacral pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | 25.0 | View |
| Tumour haemorrhage | SYSTEMATIC_ASSESSMENT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 25.0 | View |
| Disturbance in attention | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Dizziness | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Paraesthesia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Peripheral sensory neuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Polyneuropathy | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Restless legs syndrome | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Tremor | SYSTEMATIC_ASSESSMENT | Nervous system disorders | 25.0 | View |
| Anxiety | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Confusional state | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Depression | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Insomnia | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Panic attack | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Restlessness | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Suicidal ideation | SYSTEMATIC_ASSESSMENT | Psychiatric disorders | 25.0 | View |
| Dysuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 25.0 | View |
| Proteinuria | SYSTEMATIC_ASSESSMENT | Renal and urinary disorders | 25.0 | View |
| Ejaculation disorder | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | 25.0 | View |
| Oedema genital | SYSTEMATIC_ASSESSMENT | Reproductive system and breast disorders | 25.0 | View |
| Chronic obstructive pulmonary disease | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Dyspnoea | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Dyspnoea exertional | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Hiccups | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Nasal congestion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Oropharyngeal pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Pleural effusion | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Pneumonitis | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Productive cough | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Upper-airway cough syndrome | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | 25.0 | View |
| Alopecia | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Dermatitis acneiform | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Dry skin | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Night sweats | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Photosensitivity reaction | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Pruritus | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Rash | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Rash maculo-papular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Rash papular | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Skin fissures | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | 25.0 | View |
| Deep vein thrombosis | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Hypertension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Jugular vein thrombosis | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |
| Orthostatic hypotension | SYSTEMATIC_ASSESSMENT | Vascular disorders | 25.0 | View |